The International Agency for Research on Cancer has published new data on the worldwide incidence of cancer in which they estimate 18.1 million new cancer cases diagnosed and 9.6 million cancer-related deaths worldwide in 2018 (ref.
1 ). These rates represent a near 30% increase in the worldwide overall incidence of cancer since 2012. Cancers of the gastrointestinal system account for ~25% of the global cancer burden and the incidence of these cancers has also been increasing 1 . One explanation for this rise in cancer rates is ageing and population growth as a result of successes in the control of infections and cardiovascular diseases. However, secular changes in factors that have clear links to cancer probably also underlie these trends. Obesity is now an established risk factor for 13 different cancers, including those of the gastrointestinal system such as oesophageal adenocarcinoma and cancers of the gastric cardia, small intestine, colorectum, pancreas, liver and gallbladder 2 . Together with type 2 diabetes mellitus (T2DM), it has been estimated that overweight and obesity could account for up to 15% of gastrointestinal cancer cases worldwide with the true proportion possibly much higher 3 . Given the rising prevalence of obesity and T2DM in nearly every region of the world, these conditions could be a growing source of cancer in the coming years 4 . The established link between obesity and gastrointestinal cancers raises important questions regarding translation of this knowledge into effective preventive measures. Clearly, maintenance of a healthy weight is an obvious step to potentially reducing risk of gastrointestinal and other obesity-related cancers. Public health strategies that reduce obesity, promote physical activity and discourage the consumption of high-calorie, obesogenic foods are gradually being implemented in many regions of the world. Although such strategies could, if successful, lead to a reduction in the burden of cancer, the indication from worldwide obesity prevalence data is that the epidemic has not yet peaked and, on the contrary, is still on the rise.
Considering the scale and the upward trend of the obesity epidemic, the high incidence of many gastrointestinal cancers might justify more direct interventions, in addition to changes at the population level, to prevent cancer in those at increased risk. For example, should we target individuals with obesity and T2DM for more directed interventional measures or more regular screening for certain malignancies such as colorectal cancer? It is important to note, however, that only a small proportion of individuals with obesity actually go on to develop gastrointestinal cancers. Additionally, many individuals of normal weight develop these cancers and, therefore, the overall predictive value of obesity for any specific cancer is low. Nevertheless, there are very strong public health reasons to conduct research on how to curb the obesity epidemic on the basis that obesity increases the risk of premature death from all causes combined. Focusing on cancer, it could be potentially more effective to identify specific biological markers or phenotypes that are common in individuals with obesity and that substantially raise the risk of gastrointestinal cancer. This information would then enable the development of tailored interventions that target the relevant biological pathways either pharmacologically or through behavioural change. Furthermore, this approach might result in biomarkers that identify individuals at increased risk of gastrointestinal cancer who would be eligible for interventions or more frequent screening where possible.
The relationship between obesity, T2DM and cancers of the gastrointestinal system suggests that metabolic dysfunction is likely an important driver of carcinogenesis. Leading biological hypotheses to explain this relationship include alterations in glucose control and insulin signalling, and upregulation of adipose-tissue-derived inflammatory pathways 5, 6 . These factors affect cellular pathways controlling proliferation, growth and immune function, and their dysregulation probably supports a pro-mitogenic, anti-apoptotic phenotype that enhances the survival of mutant clones and neoplastic lesions, thereby increasing the risk of cancer development. For colorectal cancer, there is general consensus that dysregulation of insulin signalling Obesity is an established risk factor for gastrointestinal cancers. Interventions that reduce the burden of obesity at both the societal and individual level and targeted interventions among those at higher risk of cancer should be developed, supported by advances in understanding of the biology that underpins the obesity-cancer link. 
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www.nature.com/nrgastro and glucose control, leading to hyperinsulinaemia and inflammation, are important biological pathways for the development of this cancer 5, 6 . For other gastrointestinal cancers, experimental and observational data on the link between obesity-related pathways and their development is lacking. Other important mechanisms are also likely at play -some examples include the role of the gut microbiota, gut hormones and adipose tissue dysregulation 5, 6 . More research is needed to understand the biology that underlies the links between obesity, metabolic dysfunction and gastrointestinal cancers.
An additional important consideration is biological variability of the obesity phenotype and whether specific obesity endotypes exist that modify cancer risk. The concept of 'healthy obesity' might be somewhat controversial; however, evidence exists to support an obesity phenotype that does not bear many of the metabolic hallmarks typically found in individuals with obesity such as hyperinsulinaemia, elevated triglyceride levels and inflammation 7 . In addition, we know that some individuals of normal weight are insulin resistanta phenotype that corresponds to what was previously termed 'Syndrome X' (ref. 8 ). We and others have published findings from large prospective cohort studies that indicate that, although obesity overall is associated with an increased risk of colorectal cancer, individuals with obesity without raised insulin levels do not have elevated risk of this malignancy 9, 10 . However, lean individuals with hyperinsulinaemia had an increased risk of colorectal cancer of a similar magnitude to individuals with obesity and hyperinsulinaemia 9, 10 . These results indicate that there is a metabolic phenotype, characterized in this case by high levels of insulin, that might be relevant for colorectal cancer and possibly other gastrointestinal cancers, and which is associated with obesity, though not necessarily exclusively. The application of new technologies such as metabolomics and proteomics to prediagnostic and prospectively collected blood speci mens might offer exciting opportunities to discover the pathophysiology of this phenotype and highlight pathways for developing preventive approaches, as well as biomarkers for identifying high-risk individuals.
A better understanding of the biology underlying the link between obesity, metabolic health and gastrointestinal cancers could provide opportunities to tailor specific preventive strategies or therapies, such as drug repurposing or behavioural interventions in susceptible individuals. An important question is: what would be the most effective balance between interventions at the popu lation level, which would include the full range from education to industrial product design to societal and living environment redesign, and the more focused medical interventions for increased risk subgroups ( fig. 1)? We do not yet have the answer to this question and to address it effectively would require translational public health research to build on the results of aetiological and mechanisms-based studies, without neglecting to adopt intervention designs that facilitate the quantitative evaluation of complementary approaches involving both medical and societal dimensions. Ongoing efforts to tackle the obesity crisis, if effective, could reduce the burden of gastrointestinal cancers. However, more direct interventions among those at elevated risk of gastrointestinal malignancies are probably required. More research on the pathways that link obesity and metabolic health to gastrointestinal cancers should be prioritized to enable the development of such preventive strategies. 
